News & Updates
Filter by Specialty:

Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial
30 Jun 2025
byAudrey Abella
In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).